晚期EGFR突变型非小细胞肺癌患者接受·203·中国肺癌杂志2022年4月第16卷第4期ChinJLungCancer,April2022,Vol.16,No.4·临床经验·DOI:10.3779/j.issn.1019-3419.2022.04.06晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析马宇翔黄岩赵洪云刘俊玲陈丽昆吴海鹰周宁宁背景与目的非小细胞肺癌（non-smallcelllungcancer,NSCLC）靶向治疗越来越受到关注，吉非替尼和厄洛替尼均被推荐用于存在表皮生长因子受体酪氨酸激酶（epidermalgrowthfactorreceptor,EGFR）基因突变的晚期NSCLC的一线治疗。本研究旨在分析比较吉非替尼和厄洛替尼在晚期NSCLC的疗效和生存获益，以及治疗成本效益。方法回顾性分析广州医保内的66例EGFR突变型的NSCLC患者。观察疗效和记录不良反应，定期随访生存预后，并追踪治疗费用。结果总共66例可评估患者，中位无进展生存期（progression-freesurvival,PFS）为15.0个月。其中吉非替尼49例，厄洛替尼17例，PFS分别为17.5个月和13.0个月（P=0.459）。皮疹发生率吉非替尼组为62.3%（31/49），厄洛替尼组为94.1%（16/17）。成本-效益比率（cost-effectivenessratio,CER）吉非替尼组为3,027元/月，厄洛替尼组为6,800元/月，增量成本-效益比率（incrementalcost-effectivenessratio,ICEA）厄洛替尼为吉非替尼的2.25倍。结论EGFR突变的晚期NSCLC患者治疗，吉非替尼和厄洛替尼有相似的疗效和生存获益，前者不良反应可能较为轻微。广州医保下，吉非替尼成本-效益比率稍优。吉非替尼；厄洛替尼；肺肿瘤；成本效益分析R734.2TheCost-effectivenessAnalysisofGefitiniborErlotinibintheTreatmentofAdvancedEGFRMutantNon-smallCellLungCancerPatientsYuxiangMA,YanHUANG,HongyunZHAO,JunlingLIU,LikunCHEN,HaiyingWU,NingningZHOUDepartmentofMedicalOncology,SunYat-senUniversityCancerCenter,Guangzhou510160,ChinaCorrespondingauthor:YanHUANG,E-mail:huangyan@https://www.sodocs.net/doc/267447644.htmlBackgroundandobjectiveTargetedtherapyinnon-smallcelllungcancer(NSCLC)hadbecomeare-searchhotspot.Bothofgefitinibanderlotinibhadalreadybeenrecommendedasfirstlinetreatmentinepidermalgrowthfactorreceptor(EGFR)mutantadvancedNSCLCpatients.ThestudyaimedtocomparetheeffectivenessandprognosisofadvancedNSCLCwithgefitiniborerlotinib,aswellasthecost-effectivenessratioofthetwodrugs.MethodsDataof66EGFRmutantNSCLCpatientswhowereincludedinGuangzhoumedicalinsurancewereanalyzed.Theefficacyandadversereactionswereevaluated.Allthepatientswerefollowed-upregularlyandthecostofthetreatmentwasrecorded.ResultsThemedianpro-gressionfreesurvival(PFS)ofallpatientswas15.0months.49patientsreceivedgefintiband17patientshaderlotinib.ThePFSforthetwogroupsofpatientswas17.5monthand13months,respectively(P=0.459).31(62.3%)patientshadrashingefitinibgroup,16(94.1%)inerlotinibgroup.Cost-effectivenessratio(CER)ingefitinibgroupwas3,027RMBpermonth,while6,800RMBinerlotinibgroup.Theincrementalcost-effectivenessratio(ICEA)oferlotinibwas2.25timesofgefitinib.ConclusionForEGFRmutantadvancedNSCLCpatients,equalefficacyandsurvivalbenefitwereobservedinpatientswithgefitinibanderlotinib.Theadversereactionwasmilderingefitinibgroupthanthatoferlotinibgroup.AndwithGuangzhoumedicalinsur-ance,gefitinibhadasuperiorcost-effectivenessratio.Gefitinib;Erlotinib;Lungneoplasms;Cost-effectivenessanalysisThisstudywassupportedbythegrantfromDepartmentofHealthofGuangdongProvinceFundProject(toLi本研究受广东省卫生厅基金（No.A2022203）资助作者单位：510160广州，中山大学附属肿瘤医院内科（通讯作者：黄岩，E-mail:huangyan@https://www.sodocs.net/doc/267447644.html）肺癌现已成为最致命的恶性肿瘤，且发病率和病死率一直呈明显的上升趋势[1]。在我国，肺癌也是发病率及病死率最...